Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGELLAN: Durvalumab and Novel Oncology Therapies in First-Line Stage IV NSCLC
NCT03819465Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Primary completion
- May 2023
- Modality
- Single-strand DNA, Antibody Conjugates, Modified DNA Oligonucleotides
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of durvalumab, danvatirsen, oleclumab, volrustomig and rilvegostomig in non-small cell lung cancer (NSCLC) (10 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events. Started Dec 2018; status: active, not recruiting.
02
Drugs
durvalumabdanvatirsenoleclumabvolrustomigrilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03819465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819465.